Nathalie Dubois-Stringfellow - 01 Apr 2026 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: SVP-CHIEF DEVELOPMENT OFFICER
Signature: /s/ Scott Willoughby, Attorney-in-Fact
Issuer symbol: SGMO
Transactions as of: 01 Apr 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Apr 2026, 16:15:20 UTC
Previous filing: 26 Feb 2026
SEC: View on sec.gov

Quoteable Key Fact

"Nathalie Dubois-Stringfellow filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 03 Apr 2026."

Quick Takeaways

This page summarizes Nathalie Dubois-Stringfellow's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
1 reported transaction and 1 derivative row are listed below.
Filing timestamp: 03 Apr 2026, 16:15.

What Changed

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dubois-Stringfellow Nathalie	SVP-CHIEF DEVELOPMENT OFFICER	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND	/s/ Scott Willoughby, Attorney-in-Fact	03 Apr 2026	0001947007

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGMO	Stock Option (Right to Buy)	Award		+800,000		$0.000000^*	800,000	01 Apr 2026	Common Stock	800,000	$0.2601	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Content

One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.